## **LISTING OF CLAIMS**

## Claims 1-21 (cancelled)

22. (new) A method of treating a FIP1L1-PDGFR $\alpha$ -induced myeloproliferative disease, which comprises administering to a mammal subject in need treatment one or more cycles of the compound of formula VII

or a salt thereof, wherein each cycle comprises administering a therapeutically effective amount of the compound of formula (VII) for a first period of from one to six weeks on from 100 percent to 50 percent of the days in the period, followed by a second period of from one to three weeks wherein the compound of formula (VII) is not administered.

23. (new) A method of treating hypereosinophilic syndrome, which comprises administering to a mammal subject in need treatment one or more cycles of the compound of formula VII

(VII)

or a salt thereof, wherein each cycle comprises administering a therapeutically effective amount of the compound of formula (VII) for a first period of from one to six weeks on from 100 percent to 50 percent of the days in the period, followed by a second period of from one to three weeks wherein the compound of formula (VII) is not administered.

24. (new) A method of claim 23 wherein the hypereosinophilic syndrome is resistant to imitanib.

25. (new) A method of claim 24 which is characterized by a T674I mutation in PDGFRα.

26. (new) A method of claim 22 wherein the daily therapeutically effective amount of the compound of formula VII is from 220 to 230 mg.

27. (new) A method of claim 23 wherein the daily therapeutically effective amount of the compound of formula VII is from 220 to 230 mg.

28. (new) A method of claim 24 wherein the daily therapeutically effective amount of the compound of formula VII is from 220 to 230 mg.

29. (new) A method of claim 25 wherein the daily therapeutically effective amount of the compound of formula VII is from 220 to 230 mg.

30. (new) A method of claim 26 wherein the daily therapeutically effective amount of the compound of formula VII is administered as three 70 to 80 mg doses.

- 31. (new) A method of claim 27 wherein the daily therapeutically effective amount of the compound of formula VII is administered at a dose of 70 to 80 mg three times a day.
- 32. (new) A method of claim 28 wherein the daily therapeutically effective amount of the compound of formula VII is administered at a dose of 70 to 80 mg three times a day.
- 33.(new) A method of claim 22 wherein the compound of formula VII is administered from 4 to 7 times a week during the first period.
- 34. (new) A method of claim 33 wherein the FIP1L1-PDGFRα-induced myeloproliferative disease is hypereosinophilic syndrome.
- 35. (new) A method of claim 34 wherein the hypereosinophilic syndrome is resistant to imitanib.
- 36. (new) A method of claim 35 which is characterized by a T674I mutation in PDGFRa.
- 37. (new) A method of claim 35 wherein the daily therapeutically effective amount of the compound of formula VII is from 220 to 230 mg.
- 38. (new) A method of claim 37 wherein the daily therapeutically effective amount of the compound of formula VII is administered as three 70 to 80 mg doses.